



**For more information contact:**

Mattson Communications, Inc.

Kathy Mattson

312-988-9352

[kathy@mattsonpr.com](mailto:kathy@mattsonpr.com)

TransMolecular, Inc.

Alyssa Vanderpool

617-995-3050 ext. 302

[vanderpool@transmolecular.com](mailto:vanderpool@transmolecular.com)

## **TransMolecular Expands Management Team**

***Names Susan Stewart as Vice President, Regulatory Affairs; Abdallah Sentissi, Ph.D. as Vice President, Manufacturing and Quality Systems; Amy Bock as Senior Director, Clinical Operations and Douglas Jacoby, Ph.D. as Senior Director, Research and Development***

Cambridge, Mass. – November 30, 2005 – TransMolecular, Inc., a biotechnology company focused on cancer drug development, today announced key additions to the company’s management team to execute its vision and growth strategy. Bringing combined experience in the scientific discoveries and commercialization field, the new team members include:

- Susan Stewart, Vice President, Regulatory Affairs
- Dr. Abdallah Sentissi, Vice President, Manufacturing and Quality Systems
- Amy Bock, Senior Director, Clinical Operations
- Dr. Douglas Jacoby, Senior Director, Research and Development

“Susan, Abdallah, Amy and Douglas bring vast experience in each of their respective areas of expertise which will be invaluable to TransMolecular,” said E. Michael Egan, President and CEO of TransMolecular.

Dr. Vernon Alvarez, TransMolecular’s Vice President of Research and Development, who has spearheaded the company’s discovery and development of new products since 2001, will also join the management team in Cambridge. Dr. Alvarez is relocating from TransMolecular’s clinical operations in Birmingham to continue to drive the company’s cancer drug development efforts.

“All five will play critical leadership roles in TransMolecular’s future growth and are outstanding additions to our research, clinical operations and commercialization team in Cambridge,” added Mr. Egan.

Susan Stewart joins TransMolecular to oversee the company’s regulatory affairs. Ms. Stewart joins TransMolecular from Genzyme Corporation, one of the world’s leading biotech companies, where she was Vice President of Regulatory Affairs and Vice President of Quality and Regulatory Affairs for MG Biotherapeutics, a joint venture of Medtronic Inc. and Genzyme. Her experience includes strategic direction for a number of clinical stage programs, as well as commercial product global registration and management of Renagel®, Synvisc®, Carticel® and Thyrogen®. She also was the regulatory lead for Genzyme collaborations with Diacrin, Inc., Cambridge Antibody Technologies, Dyax, Inc. and Medtronic.

Prior to these positions, Ms. Stewart rose to Senior Director of Regulatory Affairs with Genzyme from Associate of Regulatory Affairs upon joining the company in 1994. Prior to Genzyme, she was Quality Assurance Supervisor for Abbot Laboratories.

Ms. Stewart has been an invited speaker in the U.S. and Europe on various regulatory affairs topics, including cell therapy, conduct of due diligence and regulation of combination products. She has published on xenotransplantation, cell therapy and change control and recently authored a chapter on conducting due diligence for the regulatory, medical and clinical affairs professional. She has conducted post graduate studies in clinical pharmacology, drug development and regulation at Tufts University School of Medicine and holds a B.A. in English from Annhurst College. Ms. Stewart is U.S. and European Union Regulatory Affairs Certified by the Regulatory Affairs Professionals Society.

“Susan is a senior regulatory professional who has more than 15 years of leading regulatory due diligence activities and has experience with virtually all types of Food and Drug Administration (FDA) submissions. She brings an outstanding record of success to TransMolecular and this important management position,” said Mr. Egan.

Dr. Abdellah Sentissi will develop and manage TransMolecular’s manufacturing and quality systems to ensure patient safety. He joins TransMolecular from BioVest

International, Inc., a cancer vaccine company, where he was Vice President, Quality Systems. In this role, he reorganized, managed and expanded the quality systems group and was responsible for all aspects of quality control (QC) testing, quality assurance (QA) affairs and validations. While at BioVest, he directed the technology transfer validation studies needed for the completion of BioVest's on-going Phase III Clinical Trial.

Prior to BioVest, Dr. Sentissi served as Vice President, Quality Systems at GenVec, Inc., a clinical-stage biopharmaceutical company developing cell and gene-based medicines to treat cancer, heart disease and ophthalmic disorders. Prior to its merger with GenVec in 2003, Dr. Sentissi managed the QC/QA group for Diacrin, a biotechnology company developing cell transplantation technology for treating human diseases. For more than 10 years, he was responsible for all aspects of testing and quality affairs and oversaw validations studies for Diacrin's pivotal clinical trials. Prior to Diacrin, Dr. Sentissi was Director of QC, QA and Technical Affairs for Endocon, Inc., a drug delivery company, and QC Manager for Massachusetts Biologic Laboratories, a vaccines and plasma derivatives manufacturing company.

Dr. Sentissi earned a Ph.D. and conducted a Post-Doctoral Fellowship in Clinical Chemistry at Northeastern University in Boston. He also holds a Masters in Med Lab Sciences from the University of California in San Francisco and a B.S. in Pharmacy from the University Paul Sabatier in Toulouse, France.

"Abdellah brings a wealth of experience creating and managing manufacturing and quality systems to TransMolecular. He understands what needs to be achieved in each stage of product development from preparing clinical trials materials to managing product manufacturing and is an excellent addition to the company's management team," added Mr. Egan.

Amy Bock joins TransMolecular's management team to work on new and existing cancer drug development and commercialization efforts. Ms. Bock brings 19 years of biotechnology experience in clinical drug development. Prior to joining TransMolecular, Ms. Bock was Director of Clinical Research in Genzyme's Clinical Strategic Development Group where she was responsible for multiple operational and technical clinical research functions. Prior to this position, Ms. Bock oversaw the gene therapy and cell based oncology clinical programs for Genzyme's Molecular Oncology Division.

Prior to this position, Ms. Bock was Associate Director of Clinical Research at Genzyme where she managed the clinical aspects of a strategic alliance with an oncology pharmaceutical company overseeing the solid tumor indications in the U.S. and a hematologic malignancy clinical program in Europe. Upon joining Genzyme, Ms. Bock oversaw the clinical drug development of the company's first major product, Cerezyme®, approved for the treatment of Gaucher Disease. Prior to Genzyme, Ms. Bock held clinical research positions with Pfizer and the Dana Farber Cancer Institute.

Ms. Bock has conducted post graduate work in cancer biology and immunology at Harvard and graduate studies towards a degree in public health. Ms. Bock earned a B.S. in biological psychology from Pine Manor College.

Dr. Douglas Jacoby joins TransMolecular's management team to work on discovering new cancer drug mechanisms using TM-601, a synthetic version of chlorotoxin that the company has developed. Dr. Jacoby joins TransMolecular from GenVec where he was Director of Research. In this role, he worked in the company's oncology program to demonstrate biological activity of treatment and determine the mechanism of action in animal models and patients. Dr. Jacoby also developed Phase II clinical protocols for new cancer indications. Prior to GenVec, Dr. Jacoby served as Director of Research at Diacrin. In this role, he was charged with the successful translation of product candidates into clinical studies in areas of neurodegenerative diseases, stroke, spinal cord injury and heart failure.

Dr. Jacoby earned a Ph.D. in biochemistry from the University of Minnesota. He conducted a Post-Doctoral Fellowship at Brandeis University and earned a B.A. in biology from Kenyon College. He has published a number of papers on his research and development efforts.

#### **About TransMolecular, Inc.**

TransMolecular, Inc. is a privately held, venture capital backed biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat diseases having inadequate pharmaceutical alternatives, including cancer and pain. Research on TransMolecular's product pipeline based on a small peptide derived from scorpion venom that is expected to be useful in treating a wide variety of cancers is ongoing. More information can be found at [www.transmolecular.com](http://www.transmolecular.com).